Morgan Stanley Sticks to Its Buy Rating for BioNTech SE (BNTX)
Morgan Stanley analyst Terence Flynn maintained a Buy rating on BioNTech SE (BNTX – Research Report) today and set a price target of $145.00.
WESA1d
Penn expecting $467M windfall from COVID-19 vaccine royalty dispute
The University of Pennsylvania expects to receive $467 million from a German COVID-19 vaccine manufacturer after the pair ...
BUCKSCO.Today on MSN3d
BioNTech Agrees to Pay $467M to Penn as Part of COVID-19 Vaccine Royalties Settlement
University of Pennsylvania will receive $467 million from BioNTech as part of a settlement in a lawsuit over COVID-19 vaccine royalties, writes John George ...
FiercePharma4d
BioNTech inks settlements with NIH, Penn in COVID-19 vaccine royalty disputes
The German drugmaker will pay the NIH $791.5 million, while the University of Pennsylvania will get up to $467 million ...
University of Pittsburgh researchers make breakthrough in children's asthma treatment
PITTSBURGH (KDKA) - University of Pittsburgh researchers have developed a new nasal swab test to determine Asthma subtype results for kids. The study which was conducted by Dr. Juan Celedón a ...
BioPharma Dive4d
Pfizer exits Sangamo pact; Roche, Ideaya strike ADC deals
Sangamo shares fell on Pfizer’s decision to hand back rights to a hemophilia gene therapy. Elsewhere, Novartis got ...
Penn’s royalties from Pfizer-BioNTech COVID-19 vaccine grow to at least $2 billion after new settlement
The new $467 million includes $400 million in royalties for the Pfizer-BioNTech vaccine from 2020 through 2023.